DNA methylation is a defining feature of mammalian cellular identity and is essential for normal development 1,2 . Most cell types, except germ cells and pre-implantation embryos 3-5 , display relatively stable DNA methylation patterns, with 70-80% of all CpGs being methylated 6 . Despite recent advances, we still have a limited understanding of when, where and how many CpGs participate in genomic regulation. Here we report the in-depth analysis of 42 whole-genome bisulphite sequencing data sets across 30 diverse human cell and tissue types. We observe dynamic regulation for only 21.8% of autosomal CpGs within a normal developmental context, most of which are distal to transcription start sites. These dynamic CpGs co-localize with gene regulatory elements, particularly enhancers and transcriptionfactor-binding sites, which allow identification of key lineage-specific regulators. In addition, differentially methylated regions (DMRs) often contain single nucleotide polymorphisms associated with celltype-related diseases as determined by genome-wide association studies. The results also highlight the general inefficiency of wholegenome bisulphite sequencing, as 70-80% of the sequencing reads across these data sets provided little or no relevant information about CpG methylation. To demonstrate further the utility of our DMR set, we use it to classify unknown samples and identify representative signature regions that recapitulate major DNA methylation dynamics. In summary, although in theory every CpG can change its methylation state, our results suggest that only a fraction does so as part of coordinated regulatory programs. Therefore, our selected DMRs can serve as a starting point to guide new, more effective reduced representation approaches to capture the most informative fraction of CpGs, as well as further pinpoint putative regulatory elements.
DNA methylation is a defining feature of mammalian cellular identity and is essential for normal development 1, 2 . Most cell types, except germ cells and pre-implantation embryos [3] [4] [5] , display relatively stable DNA methylation patterns, with 70-80% of all CpGs being methylated 6 . Despite recent advances, we still have a limited understanding of when, where and how many CpGs participate in genomic regulation. Here we report the in-depth analysis of 42 whole-genome bisulphite sequencing data sets across 30 diverse human cell and tissue types. We observe dynamic regulation for only 21.8% of autosomal CpGs within a normal developmental context, most of which are distal to transcription start sites. These dynamic CpGs co-localize with gene regulatory elements, particularly enhancers and transcriptionfactor-binding sites, which allow identification of key lineage-specific regulators. In addition, differentially methylated regions (DMRs) often contain single nucleotide polymorphisms associated with celltype-related diseases as determined by genome-wide association studies. The results also highlight the general inefficiency of wholegenome bisulphite sequencing, as 70-80% of the sequencing reads across these data sets provided little or no relevant information about CpG methylation. To demonstrate further the utility of our DMR set, we use it to classify unknown samples and identify representative signature regions that recapitulate major DNA methylation dynamics. In summary, although in theory every CpG can change its methylation state, our results suggest that only a fraction does so as part of coordinated regulatory programs. Therefore, our selected DMRs can serve as a starting point to guide new, more effective reduced representation approaches to capture the most informative fraction of CpGs, as well as further pinpoint putative regulatory elements.
Changes in DNA methylation patterns and the resulting DMRs have been the focus of numerous studies in the context of normal development 7 and disease 8 . These studies have characterized many different DMR classes including partially methylated domains 9 , condition-specific 10 , cell-type-specific 9,11-13 and tissue-specific DMRs 14, 15 , as well as DMRs arising in diseases such as cancer 15, 16 . Owing to the relatively small fraction of genomic CpGs assayed or small sample cohorts, the question of what fraction of genomic CpGs changes its methylation state in the context of normal development as well as their regulatory context remains underexplored.
In this study, we systematically investigated the DNA methylation state of most human autosomal CpGs to determine those that show dynamic changes and hence may participate in genome regulation in a developmental context (dynamic CpGs). In total, we included 42 wholegenome bisulphite sequencing (WGBS) data sets, comprising a range of human cell and tissue types (n 5 30). The combined 40.4 billion reads enabled us to assay 25.71 million autosomal CpGs ($53 coverage in at least $50% of all samples; 96% of all hg19 autosomal CpGs) (Supplementary Table 1 ). We organized the samples into four classes: human embryonic stem (ES) cells and human ES-cell-derived cell populations, primary cells, disease conditions, and long-term cultured cell lines ( Fig. 1a and Supplementary Table 1 ). On a global scale, human ES cells and their derivatives exhibit the highest DNA methylation levels, followed by primary cells (,5% less), which is in sharp contrast to the global hypomethylation observed in colon cancer (,10-15% less) and longterm cultured cell lines (10-30% less).
Focusing initially on our developmental sample set (n 5 24 total, ES cells, in-vitro-derived cell types and primary cells; Supplementary  Table 1 ) we identified ,5.6 million dynamic CpGs (minimum methylation difference $ 0.3, false discovery rate (FDR) 5 10.4%, 21.8% of captured autosomal CpGs; Fig. 1b , Supplementary Fig. 1e and Supplementary Information) distributed across 716,087 discrete DMRs (19.2% of the mappable human genome; Supplementary Table 2 ). In addition to this moderately stringent cut-off, we also tested thresholds as low as 10% methylation difference that may account for DNA methylation changes arising from relevant small subpopulations in heterogeneous tissue samples or noise, but still only find 10.4 million CpGs to be dynamic ( Supplementary Fig. 1a-d) .
Focusing on the more stringent set ($0.3 difference), we find approximately 70% are on average highly methylated (.75% methylation ratio), whereas less than 2% are on average unmethylated (,10% methylation ratio) ( Supplementary Fig. 1h ). In line with this observation, we find that hypomethylation of DMRs shows greater sample specificity than hypermethylation ( Fig. 1c ). Interestingly, most of the DMRs are small (.75% are smaller than 1 kilobase (kb); Supplementary Fig. 1i ) and located distal to transcription start sites ( Supplementary Fig. 1j ). However, the average variation in DNA methylation levels across all RefSeq promoters (n 5 30,090) does still exhibit a clear increase specifically at the transcription start sites, with most of this variation occurring at intermediate and low CpG density promoters ( Fig. 1d ). For CpG islands in general, we observe distinct dynamic regimes, highlighting that different classes of CpG islands are probably subject to different modes of regulation 12, 17, 18 (Fig. 1d , bottom). Consistent with previous reports 15 , we find CpG island shores (regions within 2 kb of an island) 15 to be among the most variable genomic regions ( Supplementary Fig. 1o ). These observations are exemplified at the OCT4 (also known as POU5F1) locus, in which the promoter and large parts of the gene body exhibit high DNA methylation dynamics, whereas the strong downstream CpG island as well as the surrounding CTCF-binding sites remain static ( Fig. 1e ). Only 12.2% of our DMR set overlap with at least one of four annotated classic, gene-centric genomic features (promoter, exon, CpG island (CGI), or CGI-shore; n 5 568,430) ( Fig. 1f ). To gain insights into the role of the remaining set, we first investigated their co-localization with DNase I hypersensitive sites across 92 distinct cell types 19 as well as a catalogue of putative enhancer elements for 31 cell and tissue types 20 . Notably, we found that 42.3% of our DMRs overlap with at least one DNase I hypersensitive site (Fig. 1f ), and 26.1% co-localize with enhancerlike regions, which cover more than 50% of all H3K27ac regions in our catalogue (n 5 285,344) and represents one of the most differentially methylated features ( Fig. 1d ). Next, we examined DMR overlap with transcription-factor-binding site (TFBS) clusters compiled from 165 transcription factors profiled by the ENCODE project 21 and uncovered a highly significant overlap of the two feature classes (odds ratio 1.14, P , 0.01 empirical test, Supplementary Information). Interestingly, we find that more than 50% of all DMRs overlap with at least one and 25% with more than three TFBSs, accounting for an additional 13.0% of DMRs ( Fig. 2a ). Consistent with this, we find markedly increased variation in DNA methylation levels specifically across TFBSs (Supplementary Fig. 2a ). In summary, we were able to attribute 64.2% of all DMRs to at least one putative gene regulatory element or coding sequence 
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( Supplementary Fig. 1e-h ), suggesting that they demarcate various classes of regulatory elements. We determined all cell-type-specific hypomethylated regions (n 5 430,250; see Supplementary Information) and investigated the enrichment for 161 ENCODE factors (excluding MBD4, SETDB1, POL2P and HDAC2 from the previous set). Notably, we observe significant enrichment of cell-type-specific transcription factors that are known to be involved in the regulation of the respective cellular states (Fig. 2b) . For instance, the top three factors enriched in HUES64-specific DMRs are OCT4, SOX2 and NANOG (Fig. 2b) . Similarly, PU.1 and TAL1 are highly enriched in CD34 cells and hepatocyte nuclear factors in adult liver (Fig. 2b) . In further support of this, motif enrichment analysis revealed many more interesting cell-type-specific transcription factor associations, such as enrichment of distinct NKX factors in fetal heart and brain, and ESRRG in fetal adrenal cells ( Supplementary Fig. 2b and Supplementary Table 3 ). Moreover, we tested whether the DMR set can be used to gain insights into the combinatorial control of cellular states by transcription factors. To that end, we determined all unmethylated (,10% methylation) PAX5 motif instances (6100 base pairs (bp)) across the human genome in CD34 or fetal brain cells (Fig. 2c ). Although both footprint sets show a large overlap (11,031 sites), regions exclusively unmethylated in CD34 or fetal brain are enriched for distinct sets of other known lineage-specific transcription factor motifs; such as PU.1 in CD34 and LMX1A or EN1 in fetal brain (Fig. 2c ). Taken together, these findings highlight that cell-type-specific DNA methylation patterns can be used to detect footprints and infer potential co-regulation by transcription factors. In fact, more than 60% of all ENCODE TFBSs are hypermethylated in most samples, but become hypomethylated very specifically in only one or two cell types (Fig. 2d ), whereas 25% are constitutively unmethylated and never change (Fig. 2d ).
Breaking down this distribution of TFBSs reveals distinct patterns of variation for different types of transcription factor ( Supplementary  Fig. 2e ). More generally, we find that DNA methylation variation across TFBSs is strongly correlated with its median methylation level and therefore the (hypo-) methylation specificity ( Supplementary Fig. 2c ), as well as the tissue specificity of transcription factor expression 22 ( Supplementary  Fig. 2d ). These observations support the notion 23 that selective transcription factor binding creates and/or maintains spatially highly constrained hypomethylated regions and confers cell type specificity.
On the basis of these findings and previous reports 24 , we asked whether DMRs are more susceptible to point mutations that are functionally consequential. Even with strict filtering criteria, we found a significant enrichment of single nucleotide polymorphisms (SNPs) in DMRs compared to genomic background as well as different sets of random control regions (odds ratio 1.06, P , 10 216 , binomial test; Supplementary  Information) . We then determined the overlap of DMRs with recently evolved human-specific CpGs, termed CpG beacons 25 , which shows a marked enrichment (odds ratio 1.37-1.6 compared to genomic background and random control regions, P , 10 216 ). This suggests overall higher genetic intra-species variability specifically at regions that change their DNA methylation state. In concordance with the increased SNP frequency, DMRs are also significantly enriched for genome-wide association study (GWAS) SNPs from the GWAS catalogue 26 (odds ratio 1.16, P 5 3.27 3 10 210 , binomial test). Similar to our observations on TFBSs, GWAS SNPs exhibit a non-random enrichment distribution across cell-type-specific DMRs (Fig. 3) . For instance, we find DMRs specific to adult liver to be enriched for liver and serum metaboliterelated GWAS SNPs, fetal heart DMRs enriched for cardiovasculardisease SNPs, and many of our blood-cell-type DMRs enriched for autoimmune disease and haematological parameter related SNPs.
It is well known that many cancers exhibit considerable DNA methylation changes 27 , we therefore compared a colon cancer to a matched control and found 532,665 differentially methylated CpGs. Forty per cent of these overlapped with the previously identified developmental dynamic set (Fig. 4a) . Similarly, 37% of differentially methylated CpGs found in Alzheimer's disease samples compared to normal controls BCL11A  GTF2F1  GATA3  SPT20  CFOS  CJUN  PBX3  ERALPHA  GATA2  BRG1  TRIM28  SIRT6  STAT2  TAL1  BATF  IKZF1  PAX5N19  NFE2  MEF2C  IRF4  HNF4G  HNF4A  FOXA1  FOXA2  MYBL2  GR  ZNF217  GATA1  ATF1  CEBPD  TEAD4   FOXA2 dEN  SREBP2  SREBP1  ZBTB33  SIX5  BRF2  MEF2A  PU.1  CEBPB  CMYC  RUNX3  ZNF274  TCF12  FOXP2  FOSL1 
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(n 5 12,408) overlapped with our previous set of developmental CpGs (4,540 out of 12,294). The most notable change in the number of dynamic CpGs occurs when comparing our developmental sample cohort to the long-term cell culture cohort, leading to the identification of 8.4 million additional dynamic CpGs (Fig. 4b ). Importantly, this expanded set differs notably in terms of their sequence features, with cancer and Alzheimer's disease dynamic CpGs residing in less conserved regions that also exhibit lower motif complexity compared to the developmental and cell culture ( Supplementary Fig. 4a, b) . The cellculture-specific CpGs exhibit increased repeat content relative to developmental CpGs, a feature that is shared with Alzheimer's disease (Fig. 4c ). Although the disease samples clearly add more dynamic CpGs, our analysis suggests a notable overlap with our previous set for CpGs that may participate in actual regulatory events. Finally, we investigated the utility and power of the reduced region set to classify accurately unknown samples or help to deconvolute a mixture of samples. We first clustered our developmental sample set based on the DMRs only ( Fig. 4d ) and found the result to be in excellent agreement with genome-wide 1-kb tiling-based clustering (Supplementary Fig. 5a ). To probe the potential of our DMR set to classify unknown samples accurately, we derived signature region sets for different sample groups. These signature regions turned out to be excellent classifiers of an unseen sample (Fig. 4e, fetal brain ). Next, we tested as a proof of principle whether it is possible to use our DMR set to infer the different cell populations present within a heterogeneous sample. To that end, we deconvoluted an in silico mixture of HUES64 and hippocampus WGBS libraries using our DNA methylation signatures. Notably, the two top hits after application of a very simple deconvolution algorithm indeed proved to be hippocampus and HUES64 (Fig. 4f ).
Our study highlights and defines a relatively small subset of all genomic CpGs that change their DNA methylation state across a large number of representative cell types. Although we expect that number to increase with more diverse cell types as more WGBS data sets becoming available, our analysis suggests that the rate of newly discovered regulatory CpGs will drop rapidly once all major cell and tissue types have been mapped, mostly owed to the fact that between tissue variability exceeds within tissue variability by one order of magnitude (Supplementary Fig. 3a, b ). Future studies are likely to fine map dynamics occurring in more specific subpopulations, giving rise to smaller changes in DNA methylation that we were unable to detect or include because of power constraints. Extreme conditions in vitro or in vivo such as loss or misregulation of the maintenance methylation machinery will affect a larger subset including many intergenic CpGs that are generally static, but most of these additional CpGs are unlikely to overlap with functional elements such as TFBSs or enhancers. In combination with the fact that sequencing of WGBS libraries is very inefficient, as about 65% of all 101-bp reads in our set did not even contain any CpGs to begin with, this amounts to an approximate, combined loss of around 80% of sequencing depth on non-informative reads and static regions. Furthermore, once defined, it will probably be sufficient in most cases to profile only a representative subset of CpGs across a comprehensive set of DMRs using an array-based 28 or hybrid-capture-based 29 technology to recover representative dynamics and measure regulatory events. Using these results as a guiding principle, we expect further improved efficiencies in mapping DNA methylation and enhance its applicability as a marker for various regulatory dynamics in normal and disease phenotypes.
METHODS SUMMARY
Biological materials and sequencing libraries. Genomic DNA was fragmented to 100-500 bp using a Covaris S2 sonicator. DNA fragments were cleaned-up, endrepaired, A-tailed and ligated with methylated paired-end adapters (purchased from ATDBio). See Supplementary Information for details. Data processing and analysis. In-house-generated WGBS libraries were aligned using MAQ 30 
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